S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NYSE:ENOV

Enovis (ENOV) Stock Forecast, Price & News

$51.66
-0.22 (-0.42%)
(As of 09/22/2023 ET)
Compare
Today's Range
$51.51
▼
$52.27
50-Day Range
$51.67
▼
$65.50
52-Week Range
$43.88
▼
$66.71
Volume
234,233 shs
Average Volume
393,417 shs
Market Capitalization
$2.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.29
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Enovis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
26.4% Upside
$65.29 Price Target
Short Interest
Bearish
5.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.06mentions of Enovis in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$14,674 Sold Last Quarter
Proj. Earnings Growth
16.81%
From $2.26 to $2.64 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

203rd out of 968 stocks

Surgical Appliances & Supplies Industry

6th out of 18 stocks

See Top Rated MarketRank™ Stocks Here

ENOV stock logo

About Enovis (NYSE:ENOV) Stock

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

ENOV Price History

ENOV Stock News Headlines

September 22, 2023 | americanbankingnews.com
Enovis Co. (NYSE:ENOV) Given Consensus Recommendation of "Buy" by Brokerages
September 21, 2023 | finance.yahoo.com
Boomi Launches World Tour, Bringing Together Visionary Leaders and Industry Experts to Prepare Businesses for the AI Revolution
September 22, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
September 18, 2023 | finance.yahoo.com
Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting
September 7, 2023 | finance.yahoo.com
Should You Invest in Enovis Corporation (ENOV)?
August 8, 2023 | finance.yahoo.com
Enovis to Participate in Upcoming Investor Conferences
August 3, 2023 | finance.yahoo.com
Enovis Corporation (ENOV) Outperformed on Improving Market Conditions
August 3, 2023 | finance.yahoo.com
Enovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook
September 22, 2023 | Legacy Research (Ad)
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
August 3, 2023 | finance.yahoo.com
Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates
July 18, 2023 | msn.com
Enovis Corporation: Things Are Looking Good As Guidance Is Raised
July 11, 2023 | finance.yahoo.com
Enovis to Host Second Quarter 2023 Results Conference Call on August 3rd
July 10, 2023 | finance.yahoo.com
A Look At The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)
July 6, 2023 | finance.yahoo.com
Enovis™ Recognized as One of America’s Greatest Workplaces 2023 by Newsweek
July 3, 2023 | finance.yahoo.com
What Makes Enovis Corporation (ENOV) a Good Investment Choice?
June 29, 2023 | finanznachrichten.de
Enovis Corporation: Enovis Completes Acquisition of Novastep
June 28, 2023 | msn.com
Needham starts Enovis at buy; cites market share growth, valuation
June 28, 2023 | finance.yahoo.com
Enovis™ Completes Acquisition of Novastep®
June 26, 2023 | markets.businessinsider.com
Enovis Above-Market Growth Potential Surge Would Come from Market Share Gains and Accretive Acquisitions: Analyst
June 2, 2023 | finance.yahoo.com
Enovis to Participate in Investor Conferences in June
May 22, 2023 | finance.yahoo.com
Enovis (NYSE:ENOV) shareholders are still up 1.1% over 5 years despite pulling back 4.3% in the past week
May 17, 2023 | marketwatch.com
Catheter Stabilization Device Market Forthcoming Trends and Share Analysis by 2031
May 17, 2023 | marketwatch.com
Surgical Bone Growth Stimulator Market Share, Size, Financial Summaries Analysis from 2023-2029 with Top Players are Orthofix, Enovis, ZimVie
May 12, 2023 | msn.com
Looking Into Enovis's Return On Invested Capital
May 12, 2023 | msn.com
Enovis upgraded at Wells Fargo on valuation
May 5, 2023 | markets.businessinsider.com
Robert W. Baird Keeps Their Buy Rating on Enovis (ENOV)
May 4, 2023 | finance.yahoo.com
Q1 2023 Enovis Corp Earnings Call
See More Headlines
Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

ENOV Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:ENOV
CUSIP
N/A
CIK
1420800
Web
www.enovis.com
Phone
302-252-9160
Fax
301-323-9001
Employees
6,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.29
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$57.00
Forecasted Upside/Downside
+26.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
22.85
P/E Growth
N/A
Net Income
$-13,290,000.00
Net Margins
-8.52%
Pretax Margin
-8.00%
Return on Equity
3.74%
Return on Assets
2.95%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
2.51
Quick Ratio
1.23

Sales & Book Value

Annual Sales
$1.56 billion
Price / Sales
1.80
Cash Flow
$6.18 per share
Price / Cash Flow
8.35
Book Value
$63.71 per share
Price / Book
0.81

Miscellaneous

Outstanding Shares
54,540,000
Free Float
51,758,000
Market Cap
$2.82 billion
Optionable
Optionable
Beta
2.05
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Matthew L. Trerotola (Age 56)
    CEO & Chairman
    Comp: $5.12M
  • Mr. Brady R. Shirley (Age 57)
    Pres, COO & Director
    Comp: $3.34M
  • Ms. Patricia A. Lang (Age 64)
    Sr. VP & Chief HR Officer
    Comp: $1.59M
  • Mr. Daniel A. Pryor (Age 55)
    Exec. VP of Strategy & Bus. Devel.
    Comp: $2.08M
  • Mr. Phillip Benjamin Berry (Age 44)
    Sr. VP & CFO
  • Mr. John Kleckner (Age 46)
    VP, Controller & Chief Accounting Officer
  • Derek Leckow
    VP of Investor Relations
  • Mr. Bradley J. Tandy (Age 64)
    Sr. VP & Gen. Counsel
  • Katie Sweet
    VP of Corp. Communication
  • Brian P. Hanigan
    Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ENOV Stock - Frequently Asked Questions

Should I buy or sell Enovis stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings or view top-rated stocks.

What is Enovis' stock price forecast for 2023?

6 analysts have issued 12-month price targets for Enovis' shares. Their ENOV share price forecasts range from $57.00 to $70.00. On average, they anticipate the company's share price to reach $65.29 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price.
View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts.

How have ENOV shares performed in 2023?

Enovis' stock was trading at $53.52 at the beginning of the year. Since then, ENOV shares have decreased by 3.5% and is now trading at $51.64.
View the best growth stocks for 2023 here.

Are investors shorting Enovis?

Enovis saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,690,000 shares, an increase of 10.2% from the August 15th total of 2,440,000 shares. Based on an average daily trading volume, of 357,800 shares, the short-interest ratio is currently 7.5 days. Currently, 5.4% of the shares of the stock are sold short.
View Enovis' Short Interest.

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ENOV earnings forecast.

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) issued its earnings results on Thursday, August, 3rd. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.08. The business had revenue of $428.50 million for the quarter, compared to analysts' expectations of $420.06 million. Enovis had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 3.74%. The company's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $0.59 earnings per share.

What ETFs hold Enovis' stock?

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Value ETF (RFV) and Dimensional US Small Cap Value ETF (DFSV).iShares U.S. Medical Devices ETF (IHI).

What guidance has Enovis issued on next quarter's earnings?

Enovis updated its FY 2023 earnings guidance on Friday, September, 22nd. The company provided EPS guidance of $2.22-$2.36 for the period, compared to the consensus earnings per share estimate of $2.31. The company issued revenue guidance of -.

What is Enovis' stock symbol?

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

Who are Enovis' major shareholders?

Enovis' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.10%), Dimensional Fund Advisors LP (5.44%), Diamond Hill Capital Management Inc. (4.05%), Thrivent Financial for Lutherans (3.25%), State Street Corp (2.81%) and Durable Capital Partners LP (2.79%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enovis' stock price today?

One share of ENOV stock can currently be purchased for approximately $51.64.

How much money does Enovis make?

Enovis (NYSE:ENOV) has a market capitalization of $2.82 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Enovis have?

The company employs 6,800 workers across the globe.

How can I contact Enovis?

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.

This page (NYSE:ENOV) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -